{"ATC Code":"R03AC02","Abbreviation":"","Aliases":["albuterol","Ventoline","Broncovaleas","Albuterol","Salbutamolum","Asthalin","Cobutolin","Salbulin","Salbuvent","Saventol"],"Biological Half-Life":"The elimination half-life of inhaled or oral salbutamol has been recorded as being between 2.7 and 5 hours while the apparent terminal plasma half-life of albuterol has been documented as being approximately 4.6 hours.","CAS":"18559-94-9","ChEBI":"CHEBI:2549","ChEMBL":"CHEMBL714","ChemicalClasses":["phenylethanolamine"],"Chirality":"racemic","Classes":["Sympathomimetic"],"Color/Form":"White to off-white crystalline solid","Drug Classes":"Breast Feeding; Lactation; Milk, Human; Anti-Asthmatic Agents; Bronchodilator Agents; Beta Adrenergic Agonists","Drug Indication":"Salbutamol is indicated for (i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm.","Drug Warnings":"Tremor appears to be the most frequent reported adverse effect of albuterol, occurring in up to 20% of patients in clinical trials with various dosage forms of the drug. Other frequently reported adverse effects of albuterol include nervousness, nausea, tachycardia, palpitations, chest pain and dizziness. ...","DrugClasses":[],"EINECS":"242-424-0","Erowid Experience Reports":[],"Esters":["acetate"],"European Community (EC) Number":"242-424-0","FDA Pharmacological Classification":"QF8SVZ843E","FullSalts":["Salbutamol sulfate","Salbutamol hydrochloride","Salbutamol tartrate"],"HMDB ID":"HMDB0001937","HeavyAtomCount":17,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Anti-Asthmatic Agents; Bronchodilator Agents; Beta Adrenergic Agonists","IUPACName":"4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol","Impurities":["(2-(benzyloxy)phenyl)methanol","albuterone","4-[2-(tert-butylamino)-1-hydroxyethyl]-2-[[2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethoxy]methyl]phenol","t-butylnorsynephrine","4-benzyl albuterol","methyl 3-acetyl-6-(benzyloxy)-2-hydroxybenzoate","methyl 3-acetyl-2,6-dihydroxybenzoate","methyl 2,3-dihydroxybenzoate","1-[3-(hydroxymethyl)-4-phenylmethoxyphenyl]ethanol","methyl 2-(benzyloxy)-5-(2-bromoacetyl)benzoate","4-(2-(tert-butylamino)-1-hydroxyethyl)-2-(methoxymethyl)phenol","methyl 2-(benzyloxy)-5-(2-oxoacetyl)benzoate","methyl 5-(2-(tert-butylamino)-1-hydroxyethyl)-2-hydroxybenzoate","n-benzyl albuterol","α-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-3-methylbenzenemethanol","methyl 2,6-dihydroxybenzoate","methyl 2-(benzyloxy)benzoate","methyl 5-acetyl-2-(benzyloxy)benzoate","4-(benzyloxy)-3-(methoxycarbonyl)benzoic acid","4′-(benzyloxy)-2-bromo-3′-methylacetophenone","methyl 2-(benzyloxy)-5-(tert-butylglycyl)benzoate","methyl 3-acetyl-2-hydroxybenzoate","methyl 5-acetyl-2,3-dihydroxybenzoate","methyl 2,4-dihydroxybenzoate","1,3-benzenedimethanol,4-hydroxy-α1-methyl-","4-hydroxy-3-methylacetophenone","4-(2-(tert-butylamino)ethyl)-2-methylphenol","benzyl albuterol methyl ester","methyl 5-acetyl-2-(benzyloxy)-4-hydroxybenzoate","2-[(1,1-dimethylethyl)amino]-1-[3-(hydroxymethyl)-4-(phenylmethoxy)phenyl]ethanone","methyl 5-acetyl-2,4-dihydroxybenzoate","4-[2-(tert-butylamino)-1-methoxyethyl]-2-(hydroxymethyl)phenol","5-(2-(tert-butylamino)-1-hydroxyethyl)-2-hydroxybenzoic acid","albuterol dimer ether","5-(2-(tert-butylamino)-1-hydroxyethyl)-2-hydroxybenzaldehyde","methyl 5-(2-bromoacetyl)-2-hydroxybenzoate","methyl salicylate","4-(2-(tert-butylamino)-1-methoxyethyl)-2-(methoxymethyl)phenol","5-hydroxy albuterol","n-benzylalbuterone","4-hydroxy-3-(methoxycarbonyl)benzoic acid","1-(4-(benzyloxy)-3-methylphenyl)ethan-1-one","n-nitroso-albuterol","1-(4-hydroxy-3-(hydroxymethyl)phenyl)ethanone","4-benzyloxy-3-hydroxymethylacetophenone","4-(2-(tert-butylamino)ethyl)-2-(hydroxymethyl)phenol","methyl 5-acetylsalicylate","4-hydroxy-3-(hydroxymethyl)-α-oxobenzeneacetaldehyde","4-hydroxy-3-(hydroxymethyl)benzaldehyde","4-(2-(tert-butylamino)-1-hydroxyethyl)-2-(5-(2-(tert-butylamino)-1-hydroxyethyl)-2-hydroxybenzyl)-6-(hydroxymethyl)phenol","α-[[(1,1-dimethylethyl)amino]methyl]-4-(phenylmethoxy)benzenemethanol"],"InChI":"InChI=1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3","InChIKey":"NDAUXUAQIAJITI-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS. (See all compounds classified as Adrenergic beta-2 Receptor Agonists.)","Melting Point":"147-149","MolecularFormula":"C\u003csub\u003e13\u003c/sub\u003eH\u003csub\u003e21\u003c/sub\u003eNO\u003csub\u003e3\u003c/sub\u003e","MolecularWeight":"239.31 g/mol","Opticalactivity":"( + / - )","Pharmacodynamics":"Salbutamol (INN) or albuterol (USAN), a moderately selective beta(2)-receptor agonist similar in structure to terbutaline, is widely used as a bronchodilator to manage asthma and other chronic obstructive airway diseases. The R-isomer, levalbuterol, is responsible for bronchodilation while the S-isomer increases bronchial reactivity. The R-enantiomer is available and sold in its pure form as levalbuterol and subsequently may produce fewer side-effects with only the R-enantiomer present - although this has not been formally demonstrated.  After oral and parenteral administration, stimulation of the beta receptors in the body, both beta-1 and beta-2, occurs because (a) beta-2 selectivity is not absolute, and (b) higher concentrations of salbutamol occur in the regions of these receptors with these modes of administration. This results in the beta-1 effect of cardiac stimulation, though not so much as with isoprenaline, and beta-2 effects of peripheral vasodilatation and hypotension, skeletal muscle tremor, and uterine muscle relaxation.  Metabolic effects such as hyperinsulinemia and hyperglycemia also may occur, although it is not known whether these effects are mediated by beta-1 or beta-2 receptors. The serum potassium levels have a tendency to fall.","Physical Description":"Solid","PrevSalts":["sulfate","hydrochloride"],"PubChemId":2083,"Record Description":["Albuterol is a member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). It has a role as a bronchodilator agent, a beta-adrenergic agonist, an environmental contaminant and a xenobiotic. It is a member of phenylethanolamines, a secondary amino compound and a member of phenols.","Salbutamol (Albuterol [USAN]) is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.","Albuterol is a beta2-Adrenergic Agonist. The mechanism of action of albuterol is as an Adrenergic beta2-Agonist.","Albuterol is a racemic mixture of the r-isomer levalbuterol and s-albuterol, a short-acting sympathomimetic agent with bronchodilator activity. Albuterol stimulates beta-2 adrenergic receptors in the lungs, thereby activating the enzyme adenylate cyclase that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP concentrations relax bronchial smooth muscle, relieve bronchospasms, and reduce inflammatory cell mediator release, especially from mast cells. Albuterol although to a lesser extent, also stimulates beta-1 adrenergic receptors, thereby increasing the force and rate of myocardial contraction.","ALBUTEROL is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 30 investigational indications. This drug has a black box warning from the FDA.","Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma. ","A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.","See also: Albuterol Sulfate (active moiety of).","Albuterol is a member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). It has a role as a bronchodilator agent, a beta-adrenergic agonist, an environmental contaminant and a xenobiotic. It is a member of phenylethanolamines, a secondary amino compound and a member of phenols.","LiverTox|Respiratory|Asthma|Beta-2 Adrenergic Agonists"],"RefCount":3,"RefCur":"","References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Salbutamol","Name":"Salbutamol","Sub":false},{"Link":"https://en.wikipedia.org/wiki/Levosalbutamol","Name":"(-)-Salbutamol","Sub":true}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q93346928","Name":"Salbutamol","Sub":false},{"Link":"https://www.wikidata.org/wiki/Q93346990","Name":"(+)-Salbutamol","Sub":true},{"Link":"https://www.wikidata.org/wiki/Q408709","Name":"(-)-Salbutamol","Sub":true}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB01001","Name":"Salbutamol","Sub":false},{"Link":"https://go.drugbank.com/drugs/DB13139","Name":"(-)-Salbutamol","Sub":true}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/2083","Name":"Salbutamol","Sub":false},{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/182176","Name":"(+)-Salbutamol","Sub":true},{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/123600","Name":"(-)-Salbutamol","Sub":true}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL714","Name":"Salbutamol","Sub":false},{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL69073","Name":"(+)-Salbutamol","Sub":true},{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1002","Name":"(-)-Salbutamol","Sub":true}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:2549","Name":"Salbutamol","Sub":false},{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8746","Name":"(-)-Salbutamol","Sub":true}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=18559-94-9","Name":"Salbutamol","Sub":false},{"Link":"https://commonchemistry.cas.org/detail?cas_rn=34271-50-6","Name":"(+)-Salbutamol","Sub":true},{"Link":"https://commonchemistry.cas.org/detail?cas_rn=34391-04-3","Name":"(-)-Salbutamol","Sub":true}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0001937","Name":"Salbutamol","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/D02147","Name":"Salbutamol","Sub":false},{"Link":"https://www.kegg.jp/entry/C11770","Name":"(-)-Salbutamol","Sub":true}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/QF8SVZ843E","Name":"Salbutamol","Sub":false},{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/5F9MRH56GE","Name":"(+)-Salbutamol","Sub":true},{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/EDN2NBH5SS","Name":"(-)-Salbutamol","Sub":true}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID5021255","Name":"Salbutamol","Sub":false},{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID001317232","Name":"(+)-Salbutamol","Sub":true},{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID80187964","Name":"(-)-Salbutamol","Sub":true}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 2083, Salbutamol. Accessed June 26, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/2083\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/2083\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Salbutamol. UNII: QF8SVZ843E. Global Substance Registration System. Accessed June 26, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/QF8SVZ843E\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/QF8SVZ843E\u003c/a\u003e"],"SMILES":"CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O","Salts":["sulfate","hydrochloride","tartrate"],"SaltsAcidCount":[1,1,1],"SaltsAmineCount":[2,1,2],"SaltsUNII":["021SEF3731","P12862PDAK","ADS4I3E22M"],"Solubility":"Soluble in ethanol, sparingly soluble in water, and very soluble in chlorform.","StereoisomerRacemic":"(RS)-Salbutamol","Stereoisomers":["(+)-Salbutamol","(-)-Salbutamol"],"StereoisomersUNII":["5F9MRH56GE","EDN2NBH5SS"],"StoreUNII":["QF8SVZ843E"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="51.882mm" version="1.2" viewBox="0 0 126.953 51.882" width="126.953mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#FF0D0D" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="52.0" stroke="none" width="127.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="120.336" x2="112.716" y1="12.743" y2="25.941"/>
                  
            <line class="bond" id="mol1bnd2" x1="112.716" x2="125.914" y1="25.941" y2="33.561"/>
                  
            <line class="bond" id="mol1bnd3" x1="112.716" x2="105.096" y1="25.941" y2="39.139"/>
                  
            <line class="bond" id="mol1bnd4" x1="112.716" x2="102.671" y1="25.941" y2="20.142"/>
                  
            <line class="bond" id="mol1bnd5" x1="96.365" x2="86.32" y1="20.142" y2="25.941"/>
                  
            <line class="bond" id="mol1bnd6" x1="86.32" x2="73.121" y1="25.941" y2="18.321"/>
                  
            <line class="bond" id="mol1bnd7" x1="73.121" x2="59.923" y1="18.321" y2="25.941"/>
                  
            <g class="bond" id="mol1bnd8">
                        
                <line x1="59.923" x2="46.72" y1="25.941" y2="18.313"/>
                        
                <line x1="57.485" x2="46.72" y1="27.349" y2="21.129"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd9" x1="46.72" x2="33.522" y1="18.313" y2="25.933"/>
                  
            <g class="bond" id="mol1bnd10">
                        
                <line x1="33.522" x2="33.527" y1="25.933" y2="41.181"/>
                        
                <line x1="35.961" x2="35.965" y1="27.34" y2="39.774"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd11" x1="33.527" x2="46.73" y1="41.181" y2="48.81"/>
                  
            <g class="bond" id="mol1bnd12">
                        
                <line x1="46.73" x2="59.928" y1="48.81" y2="41.19"/>
                        
                <line x1="46.73" x2="57.489" y1="45.994" y2="39.782"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd13" x1="59.923" x2="59.928" y1="25.941" y2="41.19"/>
                  
            <line class="bond" id="mol1bnd14" x1="33.527" x2="23.607" y1="41.181" y2="46.908"/>
                  
            <line class="bond" id="mol1bnd15" x1="33.522" x2="20.322" y1="25.933" y2="18.315"/>
                  
            <line class="bond" id="mol1bnd16" x1="20.322" x2="10.403" y1="18.315" y2="24.044"/>
                  
            <line class="bond" id="mol1bnd17" x1="73.121" x2="73.121" y1="18.321" y2="7.002"/>
                  
            <g class="atom" id="mol1atm5">
                        
                <path d="M101.459 20.771h-.721l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .357 .024 .732v2.739h-.566v-4.9h.715l2.607 4.055h.03q-.006 -.108 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.769h.578v4.9z" fill="#3050F8" stroke="none"/>
                        
                <path d="M101.322 15.31h-.619v-2.286h-2.513v2.286h-.613v-4.9h.613v2.072h2.513v-2.072h.619v4.9z" fill="#3050F8" stroke="none"/>
                      
            </g>
                  
            <g class="atom" id="mol1atm14">
                        
                <path d="M22.588 48.798q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.245 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.733 .0 1.233 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM18.724 48.798q.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .523 -.393 1.452z" stroke="none"/>
                        
                <path d="M17.508 51.251h-.619v-2.286h-2.513v2.286h-.613v-4.9h.613v2.072h2.513v-2.072h.619v4.9z" stroke="none"/>
                      
            </g>
                  
            <g class="atom" id="mol1atm16">
                        
                <path d="M9.385 25.934q-.0 .756 -.256 1.327q-.256 .566 -.756 .882q-.5 .315 -1.245 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.733 -.0 1.233 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM5.521 25.934q.0 .923 .387 1.458q.393 .53 1.22 .53q.84 .0 1.221 -.53q.387 -.535 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.523 -1.209 -.523q-.833 -.0 -1.226 .523q-.393 .524 -.393 1.453z" stroke="none"/>
                        
                <path d="M4.305 28.387h-.62v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.62v4.9z" stroke="none"/>
                      
            </g>
                  
            <g class="atom" id="mol1atm17">
                        
                <path d="M75.381 3.078q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.245 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.733 .0 1.233 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM71.517 3.078q.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .523 -.393 1.452z" stroke="none"/>
                        
                <path d="M79.687 5.531h-.619v-2.286h-2.513v2.286h-.613v-4.9h.613v2.072h2.513v-2.072h.619v4.9z" stroke="none"/>
                      
            </g>
                
            <line class="hi" id="mol1bnd4" stroke="#3050F8" x1="102.671" x2="107.6935" y1="20.142" y2="23.0415"/>
            <line class="hi" id="mol1bnd4" stroke="#3050F8" x1="102.671" x2="107.6935" y1="20.142" y2="23.0415"/>
            <line class="hi" id="mol1bnd5" stroke="#3050F8" x1="96.365" x2="91.3425" y1="20.142" y2="23.0415"/>
            <line class="hi" id="mol1bnd5" stroke="#3050F8" x1="96.365" x2="91.3425" y1="20.142" y2="23.0415"/>
            <line class="hi" id="mol1bnd14" stroke="#FF0D0D" x1="23.607" x2="28.567" y1="46.908" y2="44.0445"/>
            <line class="hi" id="mol1bnd14" stroke="#FF0D0D" x1="23.607" x2="28.567" y1="46.908" y2="44.0445"/>
            <line class="hi" id="mol1bnd16" stroke="#FF0D0D" x1="10.403" x2="15.3625" y1="24.044" y2="21.1795"/>
            <line class="hi" id="mol1bnd16" stroke="#FF0D0D" x1="10.403" x2="15.3625" y1="24.044" y2="21.1795"/>
            <line class="hi" id="mol1bnd17" stroke="#FF0D0D" x1="73.121" x2="73.121" y1="7.001999999999999" y2="12.6615"/>
            <line class="hi" id="mol1bnd17" stroke="#FF0D0D" x1="73.121" x2="73.121" y1="7.001999999999999" y2="12.6615"/>
        </g>
          
    </g>
    
</svg>
","Subjective Effects":{"Cognitive Effects":["Thought acceleration","Wakefulness"],"Physical Effects":["Stamina enhancement","Dehydration","Dry mouth","Restless legs","Shakiness","Abnormal heartbeat","Increased blood pressure","Increased heart rate","Vasoconstriction"],"Sensory Effects":[]},"Therapeutic Uses":"Bronchodilator; tocolytic","Title":"Salbutamol","UNII":"QF8SVZ843E","Wikidata":"Q93346928","Wikipedia":"Salbutamol","XLogP":0.3}